|Bid||4.57 x 800|
|Ask||5.04 x 900|
|Day's Range||4.40 - 5.05|
|52 Week Range||3.36 - 17.44|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||13.67|
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
GAITHERSBURG, Md., May 13, 2022 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced that, on May 10, 2022, the Compensation Committee of MaxCyte’s Board of Directors granted stock options to purchase an aggregate of 73,700 shares of MaxCyte’s c
MaxCyte, Inc. ( LON:MXCT ) shareholders might be concerned after seeing the share price drop 28% in the last quarter...